New UK human studies funded by £60 million investment to research Parkinson’s, addiction and immunity

7 October 2014

Three new research programs have been funded as part of a £60 million ($96 million) investment from the UK’s Medical Research Council (MRC).

The latest phase of the MRC’s Experimental Medicine Challenge will provide new insights into the biological mechanisms of Parkinson’s disease, reduced immunity in the elderly and the way the gut and brain interact to influence addictive behavior. The research programs aim to deliver a step-change in understanding of disease by using human volunteers in experimental studies.

The MRC said human experiments could help scientists to identify new opportunities to intervene with medical treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >